X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (501) 501
index medicus (399) 399
raltegravir potassium (395) 395
hiv infections - drug therapy (379) 379
male (295) 295
female (285) 285
raltegravir (262) 262
adult (253) 253
infectious diseases (250) 250
middle aged (214) 214
pyrrolidinones - administration & dosage (201) 201
anti-hiv agents - administration & dosage (181) 181
hiv (176) 176
pharmacology & pharmacy (162) 162
hiv infections - virology (153) 153
pyrrolidinones - therapeutic use (145) 145
immunology (144) 144
anti-hiv agents - therapeutic use (127) 127
hiv-1 - drug effects (127) 127
treatment outcome (123) 123
antiretroviral therapy (116) 116
microbiology (115) 115
antiviral agents (110) 110
viral load (107) 107
drug therapy, combination (106) 106
hiv integrase inhibitors - therapeutic use (106) 106
pharmacokinetics (103) 103
pyrrolidinones - adverse effects (103) 103
safety (95) 95
hiv infection (94) 94
pyrrolidinones - pharmacokinetics (92) 92
hiv integrase inhibitors - administration & dosage (91) 91
virology (89) 89
dosage and administration (88) 88
cd4 lymphocyte count (85) 85
drug interactions (85) 85
drug therapy (85) 85
anti-hiv agents - adverse effects (83) 83
pyrrolidinones - pharmacology (81) 81
infection (77) 77
efficacy (76) 76
raltegravir potassium - administration & dosage (74) 74
therapy (71) 71
hiv integrase inhibitors - adverse effects (70) 70
hiv-1 (70) 70
aids/hiv (69) 69
drug administration schedule (66) 66
research (66) 66
young adult (65) 65
anti-hiv agents - pharmacokinetics (63) 63
hiv-1 - genetics (63) 63
human immunodeficiency virus--hiv (63) 63
integrase inhibitor (61) 61
hiv integrase inhibitors - pharmacokinetics (60) 60
tenofovir (59) 59
hiv integrase inhibitors - pharmacology (58) 58
raltegravir potassium - therapeutic use (57) 57
drug resistance, viral (56) 56
rna, viral - blood (56) 56
adolescent (52) 52
antiretroviral drugs (52) 52
aids (51) 51
anti-hiv agents - pharmacology (51) 51
care and treatment (49) 49
double-blind (49) 49
health aspects (49) 49
analysis (48) 48
integrase (48) 48
integrase inhibitor raltegravir (47) 47
mk-0518 (47) 47
combination therapy (46) 46
ritonavir - administration & dosage (46) 46
aged (45) 45
hiv-1 - isolation & purification (45) 45
darunavir (44) 44
integrase inhibitors (44) 44
protease inhibitors (44) 44
antiretroviral therapy, highly active - methods (43) 43
hiv infections - immunology (43) 43
adenine - analogs & derivatives (42) 42
antiretroviral therapy, highly active (42) 42
hiv infections - blood (39) 39
ritonavir - therapeutic use (39) 39
hiv protease inhibitors - administration & dosage (38) 38
ritonavir (38) 38
abridged index medicus (37) 37
emtricitabine (37) 37
efavirenz (36) 36
hiv-1-infected patients (36) 36
pyrrolidinones (36) 36
treatment-experienced patients (36) 36
treatment-naive patients (36) 36
hiv protease inhibitors - therapeutic use (35) 35
prospective studies (35) 35
raltegravir potassium - adverse effects (34) 34
replication (34) 34
animals (33) 33
article (33) 33
hiv-infected patients (33) 33
viral load - drug effects (33) 33
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AIDS, ISSN 0269-9370, 08/2017, Volume 31, Issue 13, pp. 1853 - 1858
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 06/2015, Volume 60, Issue 12, pp. 1842 - 1851
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2015, Volume 61, Issue 5, pp. 809 - 816
Journal Article
by Pressiat, Claire and Hirt, Déborah and Treluyer, Jean-Marc and Zheng, Yi and Morlat, Philippe and Naqvi, Alice and Tran, Laurent and Viard, Jean-Paul and Avettand-Fenoel, Véronique and Rouzioux, Christine and Meyer, Laurence and Cheret, Antoine and Saint-Jacques, Saint-Jacques and Hoen, B and Bourdeaux, C and Delfraissy, J.F and Goujard, C and Amri, I and Fourn, E and Quertainmont, Y and Môle, M and Rami, A and Durel, A and Diemer, M and Parrinello, M and Allégre, T and Lafeuillade, A and Hittinger, G and Lambry, V and Carrerre, M and Philip, G and Duvivier, C and Consigny, P.H and Charlier, C and Shoai, M and Touam, F and Pialoux, G and Slama, L and L'Yavanc, T and Mathurin, P and Adda, A and Berrebi, V and Salmon, D and Chakvetadze, E and Tassadit, T and Ousseima, E and Pietri, P and Levy, Y and Lascaux, A.S and Lelievre, J.D and Giovanna, M and Dominguez, S and Dumont, C and Katlama, C and Valentin, M.A and Seang, S and Schneider, L and Kiorza, N and Chermak, A and Abdallah, S.B and Ben, S and Simon, A and Pichon, F and Pauchard, M and Molina, J.M and Lascoux, C and Ponscarme, D and De Verdiere, N. Colin and Scemla, A and De Castro, N and Rachline, A and Garrait, V and Rozenbaum, W and Ferret, S and Balkan, S and Clavel, F and Tourdjman, M and Lafaurie, M and Aslan, A and Goguel, J and Thierry, S.M and De Lastours, V and Gallien, S and Pavie, J and Delgado, J and Mededji, C and Hôpital, R. Veron and Chennebault, J.M and Vandamme, Y.M and Fialaire, P and Rehaiem, S and Rabier, V and Abgueguen, P and Abel, S and Pierre-Franéois, S and Baringhton, C and Morlat, P and Vandenhende, M.A and Bernard, N and Lacoste, D and ... and OPTIPRIM Study Grp and OPTIPRIM Study Group
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 04/2018, Volume 73, Issue 4, pp. 1020 - 1024
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 11/2016, Volume 68, Issue 11, pp. 1359 - 1365
Objectives Raltegravir is a human immunodeficiency virus (HIV)‐1 integrase strand transfer inhibitor currently marketed at a dose of 400 mg twice daily (BID).... 
interaction | pharmacokinetics | calcium carbonate | once‐daily | aluminium and magnesium hydroxide | once-daily | ACID-REDUCING AGENTS | THERAPY | VOLUNTEERS | PHARMACOLOGY & PHARMACY | HIV-INTEGRASE INHIBITOR | Raltegravir Potassium - adverse effects | Area Under Curve | Magnesium - administration & dosage | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Male | Metabolic Clearance Rate | Aluminum Hydroxide - administration & dosage | HIV Integrase Inhibitors - administration & dosage | Drug Interactions | Polypharmacy | Antacids - adverse effects | HIV Infections - diagnosis | Adult | Female | Calcium Carbonate - administration & dosage | Magnesium - adverse effects | Raltegravir Potassium - pharmacokinetics | Drug Administration Schedule | Administration, Oral | HIV Infections - virology | HIV Integrase Inhibitors - pharmacokinetics | Magnesium Hydroxide - adverse effects | Calcium Carbonate - adverse effects | Aluminum Hydroxide - adverse effects | Magnesium Hydroxide - administration & dosage | HIV Integrase Inhibitors - adverse effects | Raltegravir Potassium - blood | HIV Infections - drug therapy | HIV Integrase Inhibitors - blood | Antacids - administration & dosage | Drug Combinations | Urine | Antiviral agents | Analysis | Electrocardiogram | Calcium carbonate | Electrocardiography | Magnesium hydroxide | HIV (Viruses) | Human immunodeficiency virus--HIV | Antacids | Magnesium
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 2017, Volume 64, Issue 11, pp. 1591 - 1596
Background. The long-term effectiveness of human immunodeficiency virus (HIV) treatments containing integrase inhibitors is unknown. Methods. We use... 
Comparative effectiveness | HIV | Cohort study | Mortality | Raltegravir | INFECTIOUS DISEASES | cohort study | EFFICACY | SAFETY | HIV-1 INFECTION ANALYSIS | raltegravir | MARGINAL STRUCTURAL MODELS | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | TRIAL | NAIVE PATIENTS | comparative effectiveness | mortality | DOUBLE-BLIND | Raltegravir Potassium - adverse effects | United States - epidemiology | HIV Infections - epidemiology | Humans | Middle Aged | Raltegravir Potassium - administration & dosage | Raltegravir Potassium - therapeutic use | Male | RNA, Viral - blood | Tenofovir - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Young Adult | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - mortality | Reverse Transcriptase Inhibitors - therapeutic use | Tenofovir - adverse effects | Benzoxazines - administration & dosage | Tenofovir - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Acquired Immunodeficiency Syndrome - drug therapy | Benzoxazines - therapeutic use | HIV Integrase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - epidemiology | Acquired Immunodeficiency Syndrome - mortality | HIV Infections - drug therapy | Viral Load - drug effects | Cohort Studies | HIV patients | Care and treatment | Dosage and administration | Efavirenz | HIV infection | Major
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 10/2017, Volume 216, Issue 7, pp. 813 - 818
Journal Article
PLoS Pathogens, ISSN 1553-7366, 2016, Volume 12, Issue 1, p. e1005381
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2015, Volume 61, Issue 8, pp. 1328 - 1335
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2015, Volume 10, Issue 2, p. e0118228
Objective To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have... 
PROTEASE INHIBITOR | METAANALYSIS | EFFICACY | SAFETY | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | DISEASE | ADULTS | ANTIRETROVIRAL THERAPY | TENOFOVIR/EMTRICITABINE | HIV Protease Inhibitors - adverse effects | HIV-1 | Raltegravir Potassium - adverse effects | Ritonavir - administration & dosage | Humans | Raltegravir Potassium - administration & dosage | Raltegravir Potassium - therapeutic use | Male | HIV Protease Inhibitors - administration & dosage | Secondary Care | HIV Integrase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Ritonavir - adverse effects | HIV Integrase Inhibitors - adverse effects | HIV Integrase Inhibitors - therapeutic use | Lopinavir - administration & dosage | Ritonavir - therapeutic use | Adult | HIV Infections - drug therapy | Lopinavir - therapeutic use | Drug Therapy, Combination | Lopinavir - adverse effects | Medical research | Low density lipoproteins | HIV (Viruses) | Blood cholesterol | Protease inhibitors | Proteases | Nucleosides | Medicine, Experimental | DNA polymerases | Drug therapy | Health aspects | HIV infection | Trans fatty acids | Lipoproteins (low density) | Therapy | RNA-directed DNA polymerase | Ritonavir | Cardiovascular disease | Randomization | Motivation | Acquired immune deficiency syndrome--AIDS | Lymphocytes | Safety engineering | Human immunodeficiency virus--HIV | Hemoglobin | Safety | Lipoproteins (high density) | Integrase | Antiretroviral drugs | Effectiveness | Hematology | Lopinavir | Durability | Proteinase inhibitors | Ribonucleic acid--RNA | Cholesterol | Adults | RNA | Acquired immune deficiency syndrome | Ribonucleic acid | AIDS | HIV | Human immunodeficiency virus
Journal Article